Does this affect the UK?

Not directly. The 503B Bulks List is a US instrument. The MHRA operates a separate framework, though it has taken its own enforcement action in this area.

Why were compounded versions available at all?

US law permits compounding of a commercially available drug during a declared shortage. The semaglutide shortage was declared over in February 2025, removing that basis.

Is research material a form of compounded GLP-1?

No. Compounded preparations are made by pharmacies for administration to people. Research material is supplied for laboratory use only and is not an alternative to any medicine.

Research & Regulatory News

The Compounded GLP-1 Crackdown

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

On 30 April 2026 the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulk Drug Substances List. If finalised, that closes the last legal pathway for most large-scale compounded GLP-1s. It followed 30 warning letters to telehealth companies in March 2026.

Key facts

Proposal date: 30 April 2026
Compounds named: Semaglutide, tirzepatide, liraglutide
Mechanism: Removal from the 503B Bulks List
Warning letters: 30 to telehealth companies, March 2026
Comment period: Closed end of June 2026
Trigger: Shortage declared over, 21 February 2025
Jurisdiction: United States — not the UK

Why compounding was legal in the first place

US compounding law permits pharmacies to prepare a version of a commercially available drug in defined circumstances, one of which is a declared shortage. When demand for semaglutide and tirzepatide outran supply, that exemption opened, and a large compounding industry grew inside it — much of it distributing through telehealth platforms rather than traditional pharmacy.

What changed

The FDA declared the semaglutide shortage over on 21 February 2025, which removed the main legal basis for compounding it. Enforcement escalated through 2026: 30 warning letters went to telehealth companies in March, and on 30 April the agency proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulk Drug Substances List — the list of ingredients large outsourcing facilities are permitted to use. A comment period ran to the end of June 2026.

The safety record behind it

The FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide as of early 2025. A substantial share involved dosing errors, several requiring hospitalisation, arising from patients drawing doses themselves from multi-dose vials rather than using a metered pen. That is a failure mode created by the presentation rather than by the molecule.

Why this is not a UK story, and why it matters here anyway

The 503B Bulks List is a US regulatory instrument with no UK equivalent, and the MHRA operates a different framework. But the underlying pattern is the same one the MHRA acted on when it opened investigations into UK retailers making therapeutic claims about peptides in April 2026: demand for incretin compounds outrunning licensed supply, and a grey market forming in the gap.

The distinction that matters most

Compounded GLP-1, licensed GLP-1 and research material are three different things and should never be conflated. A compounded preparation is made by a pharmacy for administration to a person. A licensed product has a marketing authorisation. Material supplied for laboratory research is neither — it is not a medicine, not a compounded preparation, not an alternative to either, and not supplied for human use. Nothing in this regulatory story creates a route from one category to another.

What happens next

Finalising the proposal could take months, and the outcome was not settled at the time of writing. If it is finalised, the practical effect is that mass compounding of these three compounds ends in the United States, leaving licensed products and clinical trials as the routes to them.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does this affect the UK?: Not directly. The 503B Bulks List is a US instrument. The MHRA operates a separate framework, though it has taken its own enforcement action in this area.
Why were compounded versions available at all?: US law permits compounding of a commercially available drug during a declared shortage. The semaglutide shortage was declared over in February 2025, removing that basis.
Is research material a form of compounded GLP-1?: No. Compounded preparations are made by pharmacies for administration to people. Research material is supplied for laboratory use only and is not an alternative to any medicine.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum